Powered by Simoa®: Ultra-Sensitive Biomarker Detection
Simoa® technology enables ultra-sensitive detection of blood-based biomarkers, allowing earlier and more precise assessment of Alzheimer’s risk – helping providers and patients make informed health decisions.
Identify Alzheimer’s risk earlier with a simple blood test. Simoa® technology enables ultra-sensitive biomarker detection, helping guide patients toward proactive brain health management and informed care decisions.
LucentAD® Complete
A comprehensive biomarker panel for assessing Alzheimer’s pathology.
LucentAD® p-Tau217
A highly specific test identifying Alzheimer’s pathology before symptoms progress.
*LucentAD tests are not standalone and are not FDA approved.
Advancing Alzheimer’s Testing
Blood-Based Precision and Convenience
Lucent Diagnostics, a Quanterix brand, advances blood-based Alzheimer’s testing with Simoa® technology. Our ultra-sensitive biomarker tests enable earlier, more accurate pathology detection, empowering providers to improve patient care and outcomes.
